1. Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system 
Eric S Lambright, MD, David J Caparrelli, MD, Abbas E Abbas, MD, Takane Toyoizumi, MD, George Coukos, MD, Katherine L Molnar- Kimber, PhD, Larry R Kaiser, MD 
The Annals of Thoracic Surgery 
Volume 68, Issue 5, Pages (November 1999)
DOI: /S (99)

2. Fig 1
In vitro cytolytic effect of HSV-1716 on Lewis lung carcinoma cells. The effect of HSV-1716 was assessed by colorimetric proliferation assay at multiple times points and variable multiplicities of infection. Values are expressed as a percentage of noninfected cells. Data is expressed in mean ± standard deviation.
The Annals of Thoracic Surgery  , DOI: ( /S (99) )

3. Fig 2
HSV-1716 one-step viral growth curve on Lewis Lung Carcinoma cells. An inoculum of virus (0.01 multiplicity of infection) was given at time zero. Burst size was calculated to be 20.
The Annals of Thoracic Surgery  , DOI: ( /S (99) )

4. Fig 3
Cell mixing study in immunocompetent C57BL/6 mice. Tumor weight on day 20. Statistical significance was found in the infected-to-uninfected groups at 1:10 (p = ) and 1:100 (p = ). Error bars reflect standard error of the mean. (LLC = Lewis lung carcinoma.)
The Annals of Thoracic Surgery  , DOI: ( /S (99) )

5. Fig 4
Cell mixing study in immunodeficient SCID mice. Tumor weight on day 20. A statistical difference was demonstrated in the 1:10 and the 1:100 versus control (p < and , respectively). Error bars reflect standard error of the mean. (LLC = Lewis lung carcinoma.)
The Annals of Thoracic Surgery  , DOI: ( /S (99) )